SG11201807778YA - Bicyclic compounds for diagnosis and therapy - Google Patents
Bicyclic compounds for diagnosis and therapyInfo
- Publication number
- SG11201807778YA SG11201807778YA SG11201807778YA SG11201807778YA SG11201807778YA SG 11201807778Y A SG11201807778Y A SG 11201807778YA SG 11201807778Y A SG11201807778Y A SG 11201807778YA SG 11201807778Y A SG11201807778Y A SG 11201807778YA SG 11201807778Y A SG11201807778Y A SG 11201807778YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- disorder
- compounds
- pct
- diagnosis
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000005856 abnormality Effects 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000035474 group of disease Diseases 0.000 abstract 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
- 210000004558 lewy body Anatomy 0.000 abstract 1
- 210000002241 neurite Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16159878 | 2016-03-11 | ||
EP16199577 | 2016-11-18 | ||
PCT/EP2017/055754 WO2017153601A1 (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807778YA true SG11201807778YA (en) | 2018-10-30 |
Family
ID=58488956
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006688RA SG10202006688RA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
SG11201807778YA SG11201807778YA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006688RA SG10202006688RA (en) | 2016-03-11 | 2017-03-10 | Bicyclic compounds for diagnosis and therapy |
Country Status (14)
Country | Link |
---|---|
US (3) | US20190071450A1 (zh) |
EP (2) | EP4001277A3 (zh) |
JP (4) | JP2019512491A (zh) |
KR (3) | KR102464274B1 (zh) |
CN (2) | CN116199700A (zh) |
AU (1) | AU2017231781C1 (zh) |
BR (1) | BR112018068066B1 (zh) |
CA (2) | CA3015947A1 (zh) |
ES (1) | ES2905539T3 (zh) |
MX (1) | MX2018010693A (zh) |
NZ (1) | NZ746901A (zh) |
RU (2) | RU2766139C2 (zh) |
SG (2) | SG10202006688RA (zh) |
WO (1) | WO2017153601A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112533928A (zh) * | 2018-06-08 | 2021-03-19 | Ac免疫有限公司 | 用于诊断的新化合物 |
CN112805280A (zh) * | 2018-06-27 | 2021-05-14 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂芳基化合物 |
WO2020041331A1 (en) * | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
US20210002712A1 (en) * | 2019-07-05 | 2021-01-07 | National University Corporation Chiba University | Phosphatidic acid sensor |
GB201914989D0 (en) * | 2019-10-16 | 2019-11-27 | Karin & Sten Mortstedt Cbd Solutions Ab | Selective ligands for TAU Aggregates |
KR20220104000A (ko) * | 2019-11-19 | 2022-07-25 | 모다크 게엠베하 | 알파-시누클레인의 응집과 관련된 질병의 진단, 치료 및 예방을 위한 신규한 화합물 |
WO2021204589A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
CN115515961A (zh) | 2020-05-07 | 2022-12-23 | Ac免疫有限公司 | 用于诊断的新化合物 |
AR123730A1 (es) * | 2020-10-15 | 2023-01-04 | Ac Immune Sa | Compuestos novedosos |
WO2023285661A1 (en) * | 2021-07-16 | 2023-01-19 | Ac Immune Sa | Novel compounds for the diagnosis of tdp-43 proteinopathies |
TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
AU2022385416A1 (en) | 2021-11-10 | 2024-05-02 | Ac Immune Sa | 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis |
WO2023083998A1 (en) | 2021-11-10 | 2023-05-19 | Ac Immune Sa | Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis |
WO2023083961A1 (en) | 2021-11-10 | 2023-05-19 | Ac Immune Sa | Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis |
CN116262744A (zh) * | 2021-12-13 | 2023-06-16 | 复旦大学 | 用于α-突触核蛋白聚集体成像的小分子探针 |
WO2023163033A1 (ja) * | 2022-02-24 | 2023-08-31 | 国立研究開発法人量子科学技術研究開発機構 | 新規化合物、αシヌクレイン凝集体結合剤及びその利用 |
WO2024059845A1 (en) * | 2022-09-15 | 2024-03-21 | The Regents Of The University Of California | Supramolecular polymer therapeutics and diagnostics |
WO2024068948A1 (en) * | 2022-09-30 | 2024-04-04 | Ac Immune Sa | Novel compounds for the diagnosis of tdp-43 proteinopathies |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05125076A (ja) * | 1991-11-06 | 1993-05-21 | Canon Inc | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置 |
CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
US6700722B2 (en) * | 2001-05-25 | 2004-03-02 | Infineon Technologies Ag | High-speed zero phase restart of a multiphase clock |
US7622479B2 (en) * | 2001-11-26 | 2009-11-24 | Takeda Pharmaceutical Company Limited | Bicyclic derivative, its production and use |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
BRPI0519124A2 (pt) * | 2004-12-17 | 2008-12-23 | Lilly Co Eli | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço |
PE20070619A1 (es) * | 2005-09-27 | 2007-07-02 | Wyeth Corp | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
KR101280333B1 (ko) * | 2006-03-28 | 2013-07-02 | 하이 포인트 파마슈티칼스, 엘엘씨 | 히스타민 h3 수용체 활성을 갖는 벤조티아졸 |
US7700616B2 (en) * | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
EA015500B9 (ru) * | 2006-06-08 | 2012-03-30 | Эли Лилли Энд Компани | Новые антагонисты мсн рецепторов |
JP5292300B2 (ja) * | 2006-11-24 | 2013-09-18 | エーシー イミューン ソシエテ アノニム | 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのn−(メチル)−1h−ピラゾール−3−アミン誘導体、n−(メチル)−ピリジン−2−アミン誘導体、およびn−(メチル)−トリゾール−2−アミン誘導体 |
BRPI0811993A2 (pt) * | 2007-05-11 | 2014-11-18 | Hoffmann La Roche | " hetarilanilinas como moduladores para beta-amiloide ". |
US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
WO2009099982A1 (en) * | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
WO2009126635A1 (en) * | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
AU2009260519A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
KR20110046503A (ko) * | 2008-07-24 | 2011-05-04 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | Ad 병인을 확인하기에 유용한 영상화제 |
WO2010021381A1 (ja) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
GB0821994D0 (en) | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CA2794018C (en) * | 2010-03-24 | 2016-05-10 | Medical University Of South Carolina | Compositions and methods for the treatment of degenerative diseases |
US20110256064A1 (en) * | 2010-04-16 | 2011-10-20 | Ac Immune, S.A. | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins |
KR101851810B1 (ko) | 2010-04-16 | 2018-04-26 | 에이씨 이뮨 에스.에이. | 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물 |
GB201012889D0 (en) * | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
WO2012007510A1 (en) * | 2010-07-14 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Compounds for binding and imaging amyloid plaques and their use |
DE102010045797A1 (de) | 2010-09-20 | 2012-03-22 | Klinikum Darmstadt Gmbh | Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel |
JP5720253B2 (ja) * | 2011-01-06 | 2015-05-20 | コニカミノルタ株式会社 | 有機エレクトロニクス素子、それを具備した表示装置及び照明装置 |
EP2560008B1 (en) * | 2011-08-18 | 2016-11-30 | Korea Institute of Science and Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
WO2013036749A1 (en) * | 2011-09-07 | 2013-03-14 | University Of Kansas | Hcv helicase inhibitors and methods of use thereof |
AU2012312452A1 (en) * | 2011-09-19 | 2014-04-10 | C2N Diagnostics | Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes |
CN104010641B (zh) * | 2011-10-27 | 2017-04-12 | 普罗塔医药公司 | 用于治疗淀粉样蛋白病和共核蛋白病的含咖啡因的化合物和组合物 |
WO2013156431A1 (en) * | 2012-04-17 | 2013-10-24 | Syngenta Participations Ag | Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives |
JP2015525241A (ja) * | 2012-06-22 | 2015-09-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 殺菌・殺カビ性ヘテロ環式化合物 |
WO2014113191A1 (en) * | 2013-01-15 | 2014-07-24 | Xiaohu Zhang | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
WO2015091584A1 (en) * | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
US10479802B2 (en) | 2014-08-29 | 2019-11-19 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
TR201815071T4 (tr) | 2014-12-02 | 2018-11-21 | Bayer Cropscience Ag | Zararlılarla mücadele maddesi olarak bisiklik bileşikler. |
EP3372601B1 (en) | 2015-10-22 | 2022-09-21 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic heterocyclic compound |
-
2017
- 2017-03-10 SG SG10202006688RA patent/SG10202006688RA/en unknown
- 2017-03-10 KR KR1020187029373A patent/KR102464274B1/ko active IP Right Grant
- 2017-03-10 RU RU2018135709A patent/RU2766139C2/ru active
- 2017-03-10 EP EP21214388.7A patent/EP4001277A3/en active Pending
- 2017-03-10 NZ NZ746901A patent/NZ746901A/en unknown
- 2017-03-10 EP EP17715405.1A patent/EP3426653B1/en active Active
- 2017-03-10 KR KR1020247007479A patent/KR20240036709A/ko active Application Filing
- 2017-03-10 CN CN202310122299.7A patent/CN116199700A/zh active Pending
- 2017-03-10 SG SG11201807778YA patent/SG11201807778YA/en unknown
- 2017-03-10 MX MX2018010693A patent/MX2018010693A/es unknown
- 2017-03-10 KR KR1020227038417A patent/KR102646115B1/ko active IP Right Grant
- 2017-03-10 CN CN201780016194.6A patent/CN109071528B/zh active Active
- 2017-03-10 CA CA3015947A patent/CA3015947A1/en active Pending
- 2017-03-10 JP JP2018548003A patent/JP2019512491A/ja active Pending
- 2017-03-10 WO PCT/EP2017/055754 patent/WO2017153601A1/en active Application Filing
- 2017-03-10 BR BR112018068066-4A patent/BR112018068066B1/pt active IP Right Grant
- 2017-03-10 RU RU2022101103A patent/RU2022101103A/ru unknown
- 2017-03-10 CA CA3224365A patent/CA3224365A1/en active Pending
- 2017-03-10 US US16/084,223 patent/US20190071450A1/en not_active Abandoned
- 2017-03-10 AU AU2017231781A patent/AU2017231781C1/en active Active
- 2017-03-10 ES ES17715405T patent/ES2905539T3/es active Active
-
2020
- 2020-06-05 US US16/894,682 patent/US11623931B2/en active Active
-
2021
- 2021-06-07 JP JP2021095111A patent/JP7297323B2/ja active Active
- 2021-08-25 JP JP2021137179A patent/JP7383304B2/ja active Active
-
2023
- 2023-02-27 US US18/114,654 patent/US20240051967A1/en active Pending
- 2023-06-26 JP JP2023104451A patent/JP2023116823A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201805195YA (en) | Composition comprising botulinum toxin | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases |